Strictinin 是一种具有口服活性的酚类化合物,可降低 Xanthine (MS-L85792) 处理的肝细胞中黄嘌呤氧化酶活性、尿酸生成量及 ERK1/2、JNK、NF-κB 和 NLRP3 炎症小体组分的活化,也可降低氧嗪酸钾处理小鼠升高的血尿酸水平及增强的黄嘌呤氧化酶活性;作为 ROR1 抑制剂,Strictinin 对高度侵袭性非雄激素依赖性前列腺癌具有抗癌活性,可诱导癌细胞凋亡 (apoptosis)、阻滞细胞周期,并抑制癌细胞的迁移、侵袭及上皮间质转化过程;此外,Strictinin 能够调节肠道菌群、抑制细菌 (bacterial) 生长与生物膜形成、加速小肠转运,还可阻断病毒的入侵与复制,因此可用于高尿酸血症、雄激素受体阴性雄激素非依赖性前列腺癌、三阴性乳腺癌、细菌感染、便秘、冠状病毒感染、龋齿以及甲型流感、乙型流感和人副流感病毒 1 型感染的相关研究。
产品编号: MS-M75085 纯度: 97.15% CAS No.: 517-46-4 分子式: C27H22O18 分子量: 634.45
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价

产品描述

Strictinin 是一种具有口服活性的酚类化合物,可降低 Xanthine (MS-L85792) 处理的肝细胞中黄嘌呤氧化酶活性、尿酸生成量及 ERK1/2、JNK、NF-κB 和 NLRP3 炎症小体组分的活化,也可降低氧嗪酸钾处理小鼠升高的血尿酸水平及增强的黄嘌呤氧化酶活性;作为 ROR1 抑制剂,Strictinin 对高度侵袭性非雄激素依赖性前列腺癌具有抗癌活性,可诱导癌细胞凋亡 (apoptosis)、阻滞细胞周期,并抑制癌细胞的迁移、侵袭及上皮间质转化过程;此外,Strictinin 能够调节肠道菌群、抑制细菌 (bacterial) 生长与生物膜形成、加速小肠转运,还可阻断病毒的入侵与复制,因此可用于高尿酸血症、雄激素受体阴性雄激素非依赖性前列腺癌、三阴性乳腺癌、细菌感染、便秘、冠状病毒感染、龋齿以及甲型流感、乙型流感和人副流感病毒 1 型感染的相关研究。

生物实验数据

生物活性 Strictinin is an orally active phenolic compound that reduces xanthine oxidase activity, uric acid production, and the activation of ERK1/2, JNK, NF-κB, and NLRP3 inflammasome components in Xanthine (MS-L85792)-treated hepatocytes, and also lowers the elevated serum uric acid levels and enhanced xanthine oxidase activity in potassium oxonate-treated mice; as a ROR1 inhibitor, Strictinin exhibits anticancer activity against highly aggressive androgen-independent prostate cancer by inducing apoptosis, blocking the cell cycle, and inhibiting cancer cell migration, invasion, and epithelial-mesenchymal transition; moreover, Strictinin can modulate gut microbiota, inhibit bacterial growth and biofilm formation, accelerate small intestinal transit, and block viral entry and replication, and is therefore applicable to research on hyperuricemia, androgen receptor-negative androgen-independent prostate cancer, triple-negative breast cancer, bacterial infection, constipation, coronavirus infection, dental caries, and influenza A, influenza B, and human parainfluenza virus type 1 infections.
体外研究
(In Vitro)

Strictinin (50-500 μM; 24 h) 仅在 500 μM 浓度下对 AML12 小鼠肝细胞表现出细胞毒性。
Strictinin (100-250 μM; 4-24 h) 抑制 Xanthine 处理的 AML12 小鼠肝细胞的 XOD 活性与尿酸 (UA) 生成,抑制该细胞的 IL-1β 表达。
Strictinin (250 μM; 6 h) 可抑制 Xanthine 诱导的 AML12 小鼠肝细胞中 ERK1/2、JNK、NF-κB 及 NLRP3 炎症小体组分 (NLRP3、ASC、caspase-1、剪切型 caspase-1) 的活化。
Strictinin (31.25-1000 μM; 72 h) 可强效抑制 PC3 细胞的活力,IC50 为 277.2 μmol/L;而其对正常 RWPE-1 细胞的毒性则低得多 (IC50 = 658.5 μmol/L)。
Strictinin (250 μM; 24-72 h) 可在 PC3 细胞中诱导显著的细胞凋亡,降低活细胞数量并增加所有凋亡细胞和死亡细胞群体,诱导 caspase 3/7 介导的细胞凋亡。
Strictinin (250 μM; 24-48 h) 可抑制 PC3、DU145 细胞中 ROR1 的表达,并阻断下游 PI3K-AKT-GSK3β 促存活信号通路,抑制细胞中 EMT 标志物 Twist1、Snail 和 MMP9 的表达。
Strictinin (125-250 μM; 24 h) 可抑制 PC3 细胞的迁移和侵袭。
Strictinin (250 μM; 48-72 h) 可在 PC3 中诱导 S 期细胞周期阻滞。
Strictinin (125-1000 μg/mL; 24-72 h) 可呈剂量依赖性降低 MDA-MB-231 和 BT-549 三阴性乳腺癌 (TNBC) 细胞的活力,其细胞毒性依赖于 ROR1 的表达。
Strictinin (62.5-125 μg/mL; 24 h) 可抑制 MDA-MB-231 和 BT-549 三阴性乳腺癌 (TNBC) 细胞中 PI3K/AKT 通路的活性。
Strictinin (125 μg/mL; 3-24 h) 可时间依赖性地抑制 AKT 和 GSK3β 的磷酸化,降低 XIAP 水平,抑制 Bad 的磷酸化,并在 MDA-MB-231 和 BT-549 三阴性乳腺癌 (TNBC) 细胞中诱导 caspase-9 的切割。
Strictinin (125-250 μg/mL) 可剂量依赖性地诱导 MDA-MB-231 和 BT-549 三阴性乳腺癌 (TNBC) 细胞发生凋亡。
Strictinin (62.5-125 μg/mL; 3-12 h post-wounding) 抑制 MDA-MB-231 和 BT-549 三阴性乳腺癌 (TNBC) 细胞的迁移和侵袭。
Strictinin 可抑制痤疮丙酸杆菌 (MIC 为 250 μM) 和表皮葡萄球菌 (MIC 为 2000 μM) 的生长。
Strictinin (4-100 µM) 可呈浓度依赖性抑制小鼠 L 细胞中 MHV 的噬斑形成,在全程共处理条件下,100 µM 时可完全阻断噬斑形成,20 µM 时可将噬斑形成率降至对照组的<25%。
Strictinin (100 µM; during infection, harvested at 12 and 24 hpi) 可在感染过程中完全消除 MHV 感染小鼠 L 细胞中的病毒核衣壳蛋白表达。
Strictinin (20-500 μM; 24 h) 可剂量依赖性地抑制变形链球菌 (Streptococcus mutans) 与远缘链球菌 (Streptococcus sobrinus) 的生物膜形成。
Strictinin (0.01-75 μM; 72 h) 对 MDCK 细胞表现出细胞毒性,72 h 后的 CC50 为 5 μM。
Strictinin (2-8 μM; 1 h inoculation + 48 h incubation) 在与病毒接种同时加入时,可抑制 MDCK 细胞中 B 型流感病毒的复制。
Strictinin (5-20 μM; 1 h inoculation + 48 h incubation) 可在与病毒接种同时加入时,以剂量依赖的方式在体外抑制 LLC-MK2 细胞中 1 型人副流感病毒的复制。
Strictinin (1-10 μM; 1 h) 可在 1 和 10 μM 浓度下抑制甲型流感病毒 A/WSN/33 (H1N1) 诱导的 COS-7 细胞半融合。

Cell Cytotoxicity Assay

Cell Line: AML12 mouse hepatocytes
Concentration: 50 μM; 100 μM; 250 μM; 500 μM
Incubation Time: 24 h
Result: Did not significantly reduce cell viability at 50, 100, or 250 μM.
Caused a statistically significant reduction in cell viability at 500 μM.

Western Blot Analysis

Cell Line: xanthine-treated AML12 mouse hepatocytes
Concentration: 250 μM (co-treated with 100 μM Xanthine)
Incubation Time: 6/24 h
Result: Inhibited xanthine-induced activation of ERK1/2, JNK, and NF-κB.
Reduced xanthine-induced upregulation of NLRP3, ASC, caspase-1, and cleaved caspase-1 protein expressions.
Significantly decreased the expression of cleaved IL-1β, particularly in xanthine-treated cells.

Cell Viability Assay

Cell Line: PC3 (androgen-receptor negative androgen-independent prostate cancer) cells, RWPE-1 (normal prostatic epithelial) cells
Concentration: 31.25, 62.5, 125, 250, 500, 1000 μM
Incubation Time: 72 h
Result: Exhibited selective cytotoxicity, with an IC50 of 277.2 μmol/L in PC3 cells.
Showed 2.4-fold lower IC50 in PC3 cells than the IC50 of 658.5 μmol/L in RWPE-1 cells.

Apoptosis Analysis

Cell Line: PC3 androgen-receptor negative androgen-independent prostate cancer cells
Concentration: 250 μM
Incubation Time: 72 h
Result: Led to a significant decrease in live PC3 cells.
Caused significant increases in early apoptotic, late apoptotic, dead, and total apoptotic cell populations compared to vehicle control.
Showed a shift from live cells to apoptotic/dead cells in representative flow cytometry profiles.
Increased the percentage of apoptotic and dead PC3 cells in a time-dependent manner.
Showed a greater effect after 48 h compared to 24 h and vehicle control, as indicated by elevated caspase 3/7 activity.

Western Blot Analysis

Cell Line: PC3 androgen-receptor negative androgen-independent prostate cancer cells
Concentration: 250 μmol/L
Incubation Time: 24 h; 48 h
Result: Reduced ROR1 protein expression, with greater reduction after 48 h than 24 h.
Decreased the ratios of p-AKT/AKT and p-GSK3β/GSK3β.
Indicated inhibition of ROR1-mediated PI3K-AKT-GSK3β pro-survival signaling.\nReduced the expression of Twist1, Snail, and MMP9 in PC3 cells.
Showed greater reductions in Twist1, Snail, and MMP9 expression after 48 h compared to 24 h.

Cell Migration Assay

Cell Line: PC3 androgen-receptor negative androgen-independent prostate cancer cells, RWPE-1 normal prostatic epithelial cells
Concentration: 125, 250 μmol/L
Incubation Time: 24 h
Result: Reduced percent wound healed in PC3 cells in a concentration-dependent manner.
Caused a significant reduction in percent wound healed in PC3 cells at 250 μmol/L compared to control.
Did not significantly change percent wound healed in RWPE-1 cells compared to control.

Cell Invasion Assay

Cell Line: PC3 androgen-receptor negative androgen-independent prostate cancer cells, RWPE-1 normal prostatic epithelial cells
Concentration: 250 μmol/L
Incubation Time: 24 h
Result: Significantly reduced the percentage area covered by invaded PC3 cells compared to control.
Did not significantly change invasion in RWPE-1 cells compared to control.

Cell Cycle Analysis

Cell Line: PC3 androgen-receptor negative androgen-independent prostate cancer cells, RWPE-1 normal prostatic epithelial cells
Concentration: 125 μmol/L; 250 μmol/L
Incubation Time: 24 h (125 μmol/L; 250 μmol/L PC3); 48 h (250 μmol/L PC3); 72 h (250 μmol/L RWPE-1)
Result: Caused an S-phase cell cycle arrest in PC3 cells, with a ~5% increase in S-phase cells after 48 h of 250 μmol/L treatment compared to control.
Caused a ~2% increase in S-phase cells in RWPE-1 cells after 250 μmol/L treatment for 72 h compared to control.
体内研究
(In Vivo)

Strictinin (400-1000 mg/kg;灌胃;每周 1 次;共 7 天) 可通过抑制肝脏黄嘌呤氧化酶活性、降低血清尿酸水平、保护肾脏免受损伤以及调节肠道菌群使其趋于更健康的组成,显著减轻氧酸钾诱导的雄性 ICR 小鼠高尿酸血症。
Strictinin (0.25-0.5 g/kg; 口服; 单次) 可通过加速小肠转运在大鼠中发挥剂量依赖性泻下作用,且不会改变食物摄入量、诱发腹泻或促进胃排空。

Animal Model: ICR (8-week-old male; hyperuricemia induced by oral gavage of potassium oxonate)
Dosage: 400 mg/kg; 700 mg/kg; 1000 mg/kg
Administration: p.o.; single weekly; 7 days
Result: Significantly reduced elevated liver xanthine oxidase activity and serum uric acid level induced by potassium oxonate.
Prevented slight renal tubular dilation damage observed in potassium oxonate-treated mice.
Significantly elevated proportions of Clostridium thermosuccinogenes, Marvinbryantia formatexigens, and Ruminococcus lactaris in gut microbiota.
Significantly reduced proportions of Clostridium aldenense, Clostridium cellulovorans, Clostridium lavalense, Clostridium saccharolyticum, Clostridium symbiosum, Ruminococcus gauvreauii, Roseburia faecis, and Ruminococcus gnavus in gut microbiota compared to potassium oxonate-only treated mice.
Caused no significant liver damage in treated groups.
Animal Model: Sprague-Dawley (male, 200-250 g)
Dosage: 0.25 g/kg; 0.5 g/kg
Administration: p.o.; single dose
Result: Increased feces weight significantly relative to controls at 6 hs post-administration (0.25 g/kg dose).
Increased feces weight significantly relative to controls at 6, 12, and 24 h post-administration, with a stronger effect at the higher dose (0.5 g/kg dose).
Showed no significant change in gastric emptying percentage relative to controls (0.5 g/kg dose).
Accelerated small intestinal transit percentage significantly relative to controls (0.5 g/kg dose).
Caused no significant differences in food intake or fecal water content relative to controls.
性状 固体
颜色 White to off-white

化学信息

分子量 634.45
分子式 C27H22O18
CAS No. 517-46-4

储存&溶解度

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 50 mg/mL (78.81 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM1.5762 mL7.8808 mL15.7617 mL39.4042 mL
5 mM0.3152 mL1.5762 mL3.1523 mL7.8808 mL
10 mM0.1576 mL0.7881 mL1.5762 mL3.9404 mL
15 mM0.1051 mL0.5254 mL1.0508 mL2.6269 mL
20 mM0.0788 mL0.3940 mL0.7881 mL1.9702 mL
25 mM0.0630 mL0.3152 mL0.6305 mL1.5762 mL
30 mM0.0525 mL0.2627 mL0.5254 mL1.3135 mL
40 mM0.0394 mL0.1970 mL0.3940 mL0.9851 mL
50 mM0.0315 mL0.1576 mL0.3152 mL0.7881 mL
60 mM0.0263 mL0.1313 mL0.2627 mL0.6567 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础